PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
23.59%
Similar revenue growth to CRWV's 23.55%. Walter Schloss would investigate if similar growth reflects similar quality.
58.38%
Cost growth above 1.5x CRWV's 19.16%. Michael Burry would check for structural cost disadvantages.
15.95%
Gross profit growth 50-75% of CRWV's 25.15%. Martin Whitman would scrutinize competitive position.
-6.19%
Margin decline while CRWV shows 1.30% expansion. Joel Greenblatt would examine competitive position.
84.42%
R&D change of 84.42% while CRWV maintains spending. Bruce Berkowitz would investigate effectiveness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.58%
Operating expenses growth above 1.5x CRWV's 17.97%. Michael Burry would check for inefficiency.
71.27%
Total costs growth above 1.5x CRWV's 18.28%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-8.54%
D&A reduction while CRWV shows 26.15% growth. Joel Greenblatt would examine efficiency.
-57.57%
EBITDA decline while CRWV shows 33.05% growth. Joel Greenblatt would examine position.
-72.17%
EBITDA margin decline while CRWV shows 7.69% growth. Joel Greenblatt would examine position.
-53.14%
Operating income decline while CRWV shows 169.93% growth. Joel Greenblatt would examine position.
-62.09%
Operating margin decline while CRWV shows 156.60% growth. Joel Greenblatt would examine position.
11.16%
Other expenses growth while CRWV reduces costs. John Neff would investigate differences.
-40.73%
Pre-tax income decline while CRWV shows 9.63% growth. Joel Greenblatt would examine position.
-52.05%
Pre-tax margin decline while CRWV shows 26.86% growth. Joel Greenblatt would examine position.
-40.71%
Tax expense reduction while CRWV shows 3.78% growth. Joel Greenblatt would examine advantage.
-40.74%
Net income decline while CRWV shows 7.67% growth. Joel Greenblatt would examine position.
-52.05%
Net margin decline while CRWV shows 25.27% growth. Joel Greenblatt would examine position.
-41.67%
EPS decline while CRWV shows 23.08% growth. Joel Greenblatt would examine position.
-41.67%
Diluted EPS decline while CRWV shows 23.08% growth. Joel Greenblatt would examine position.
-0.01%
Share count reduction while CRWV shows 20.32% change. Joel Greenblatt would examine strategy.
0.13%
Diluted share reduction exceeding 1.5x CRWV's 20.32%. David Dodd would verify capital allocation.